September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study
Author Affiliations & Notes
  • Vittorio Capuano
    Morphological & Surgical Sci, Centre hospitalier Intercommunal de Créteil, Créteil, France
  • OUBRAHAM-MEBROUKINE Hassiba
    Ophtalmology, Private practice, Montargis, France
  • Benjamin Wolff
    Fondation Rothschild, Paris, France
  • Salomon Y Cohen
    Centre Imagerie et Laser, Paris, France
  • Catherine P Garcher
    Ophtalmology, CHU Dijon, Dijon, France
  • Jean-Francois Korobelnik
    Hôpital Pellegrin, Bordeaux, France
  • Ramin Tadayoni
    Hôpital Lariboisiére-Ophtalmologie, Paris, France
  • Christian Delhay
    Centre d’ophtalmologie du Mené-Ténénio, Vannes, France
  • Audrey Derveloy
    Novartis Pharma SAS, Rueil-Malmaison, France
  • Eric H Souied
    Morphological & Surgical Sci, Centre hospitalier Intercommunal de Créteil, Créteil, France
  • Footnotes
    Commercial Relationships   Vittorio Capuano, None; OUBRAHAM-MEBROUKINE Hassiba, Allergan (C), Bayer (C), Novartis (C); Benjamin Wolff, Allergan (C), Bayer (C), Novartis (C); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C); Catherine Garcher, Alcon (C), Allergan (C), B+L (C), Bayer (C), Novartis (C), Thea (C); Jean-Francois Korobelnik, Alcon (C), Alimera (C), Allergan (C), Bayer (C), Horus (C), Novartis (C), Roche (C), Thea (C), Zeiss (C); Ramin Tadayoni, Alcon (C), Allergan (C), B+L (C), Bayer (C), FCI (C), Genentech (C), Novartis (C), Roche (C), Thrombogenics (C), Zeiss (C); Christian Delhay, None; Audrey Derveloy, Novartis (E); Eric Souied, Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support  Novartis
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 534. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Vittorio Capuano, OUBRAHAM-MEBROUKINE Hassiba, Benjamin Wolff, Salomon Y Cohen, Catherine P Garcher, Jean-Francois Korobelnik, Ramin Tadayoni, Christian Delhay, Audrey Derveloy, Eric H Souied; Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):534.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : LUMINOUS™ (NCT01318941; initiated March 2011) is the largest, prospective, observational, global study in the field of medical retina. LUMINOUS™ is an ongoing 5-year study that is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life associated with ranibizumab (RBZ) 0.5 mg treatment across all approved indications in 30,000 patients from routine clinical practice. We present the 1-year data from the French patients included in LUMINOUS™.

Methods : Overall, 17, 545 adult patients with neovascular age-related macular degeneration (nAMD) were enrolled before March 2014; of these 9125 adult nAMD patients with a potential for 1-year follow-up were enrolled before March 2013. We analyzed the baseline characteristics of nAMD patients that were enrolled in France before March 2014 and the 1-year data from the French cohort.

Results : Baseline characteristics of the French and the global nAMD cohorts are shown in Table 1. Both the French and the global cohorts had similar mean baseline visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letter score; French/global nAMD cohorts: VA, 58.6/54.3). A higher proportion of patients in the French cohort had pigment epithelium detachment (PED) than those in the global cohort (68.0% versus 42.4%). In the global cohort, the 1-year data showed that on average treatment-naïve patients gained VA from baseline whilst those previously treated with RBZ either gained or maintained VA, with a relatively low number of injections and visits (Table 2). The 1-year data for the French cohort are expected in February 2016.

Conclusions : The French nAMD patients enrolled in the LUMINOUS™ study were slightly older and had similar baseline VA, a higher proportion had PED, and a similar proportion had non-ocular comorbidities at baseline compared with the global nAMD cohort. The 1-year follow-up data from the French cohort will provide an invaluable source of information from a diverse group of patients currently underrepresented in randomized clinical trials.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Table 1. Baseline characteristics of the French and the global nAMD patients enrolled before March 2014

Table 1. Baseline characteristics of the French and the global nAMD patients enrolled before March 2014

 

Table 2. Outcomes at Year 1 of the global nAMD patients enrolled before March 2013

Table 2. Outcomes at Year 1 of the global nAMD patients enrolled before March 2013

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×